CY1109852T1 - Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη - Google Patents

Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη

Info

Publication number
CY1109852T1
CY1109852T1 CY20101100194T CY101100194T CY1109852T1 CY 1109852 T1 CY1109852 T1 CY 1109852T1 CY 20101100194 T CY20101100194 T CY 20101100194T CY 101100194 T CY101100194 T CY 101100194T CY 1109852 T1 CY1109852 T1 CY 1109852T1
Authority
CY
Cyprus
Prior art keywords
protector
limitation
calcium
cancer risk
risk
Prior art date
Application number
CY20101100194T
Other languages
English (en)
Inventor
John A Baron
Original Assignee
Trustees Of Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trustees Of Dartmouth College filed Critical Trustees Of Dartmouth College
Publication of CY1109852T1 publication Critical patent/CY1109852T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μια μέθοδος προαγωγής της υγείας του προστάτη σε ένα υποκείμενο που περιλαμβάνει τη χορήγηση μιας δόσης ασβεστίου στο υποκείμενο. Συγκεκριμένα παρέχεται μια μέθοδος περιορισμού του κινδύνου καρκινωμάτων του προστάτη, που περιλαμβάνει χορήγηση μιας δόσης στοιχειακού ασβεστίου αποτελεσματικής για τη μείωση καρκίνου του προστάτη. Για παράδειγμα, 1200 mg στοιχειακού ασβεστίου (που παρέχεται σε 3000 mg ανθρακικού ασβεστίου) που χορηγείται δυο φορές ημερησίως είχε ως αποτέλεσμα μειωμένο κίνδυνο καρκίνου του προστάτη.
CY20101100194T 2001-02-16 2010-02-25 Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη CY1109852T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26925601P 2001-02-16 2001-02-16
EP02717476A EP1365810B1 (en) 2001-02-16 2002-02-14 Calcium supplementation to reduce prostate cancer risk

Publications (1)

Publication Number Publication Date
CY1109852T1 true CY1109852T1 (el) 2014-09-10

Family

ID=23026481

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100194T CY1109852T1 (el) 2001-02-16 2010-02-25 Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη

Country Status (15)

Country Link
EP (1) EP1365810B1 (el)
CN (1) CN1267154C (el)
AT (1) ATE454168T1 (el)
AU (1) AU2002248474B2 (el)
CA (1) CA2438426C (el)
CY (1) CY1109852T1 (el)
DE (1) DE60234995D1 (el)
DK (1) DK1365810T3 (el)
ES (1) ES2337660T3 (el)
IL (2) IL157408A0 (el)
MX (1) MXPA03007307A (el)
NZ (1) NZ527609A (el)
PT (1) PT1365810E (el)
WO (1) WO2002066065A1 (el)
ZA (1) ZA200306470B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005022953A1 (de) * 2005-05-19 2006-11-23 Chemische Fabrik Budenheim Kg Nahrungsergänzungsmittel
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5886012A (en) * 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers

Also Published As

Publication number Publication date
IL157408A (en) 2010-12-30
ATE454168T1 (de) 2010-01-15
CA2438426C (en) 2011-03-15
ES2337660T3 (es) 2010-04-28
EP1365810B1 (en) 2010-01-06
CA2438426A1 (en) 2002-08-29
CN1531443A (zh) 2004-09-22
DK1365810T3 (da) 2010-05-10
EP1365810A1 (en) 2003-12-03
IL157408A0 (en) 2004-03-28
EP1365810A4 (en) 2004-08-11
WO2002066065A1 (en) 2002-08-29
CN1267154C (zh) 2006-08-02
ZA200306470B (en) 2004-02-10
NZ527609A (en) 2004-04-30
AU2002248474B2 (en) 2007-04-26
PT1365810E (pt) 2010-03-22
DE60234995D1 (de) 2010-02-25
MXPA03007307A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
EG25822A (en) Quinolinyl-pyrrolopyrazoles
ATE312635T1 (de) Ventilanordnung
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
GB9925958D0 (en) Therapeutic use
AU1249902A (en) Effective antitumour treatments
MY164077A (en) Compositions and uses of et743 for treating cancer
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
HK1048944B (zh) 多西他奇在製備用於治療肝細胞癌的藥物中的用途
CY1109852T1 (el) Συμπληρωμα ασβεστιου για τον περιορισμο του κινδυνου καρκινου του προστατη
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU3885799A (en) Antidepressant therapy
EP1056458A4 (en) METHODS FOR TREATING PAIN, INCLUDING CHRONIC AND WOMAN-SPECIFIC PAIN
IL159770A0 (en) Calcium salts with cytotoxic activity
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer
MXPA03006359A (es) Metodo para tratamiento del cancer.
MD1473G2 (ro) Remediu antiherpetic
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
IL151878A0 (en) Pharmaceutical compositions containing t3
UA38479A (uk) Спосіб моделювання остеопорозу
EP1385497A4 (en) METHOD FOR PREVENTING OR TREATING BREAST CANCER, PROSTATE AND / OR COLUMN OF UTERUS USING N, N-DIMETHYLGLYCIN
PL367628A1 (en) Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia
RU99102760A (ru) Способ лечения рака тела матки
UA10754A (uk) Спосіб лікуваhhя артеріальhих гіпертеhзій різhого геhезу
UA43619A (uk) Бетатирон - пролонгований антигіпертензивний засіб нової генерації